Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A Eastham, Thomas A Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E Ippolito, Michael R Kuettel, Joshua M Lang, Tamara Lotan, Rana R McKay, Todd Morgan, George Netto, Julio M Pow-Sang, Robert Reiter, Mack Roach, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Dorothy A Shead, Jenna Snedeker, Deborah A Freedman-Cass
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer...
October 2023: Journal of the National Comprehensive Cancer Network: JNCCN